Company: INMB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001213900-25-041072
Chunk: 56

Company: Inmune Bio, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 2
Chunk 56
---
 candidates. This is due to the numerous risks and uncertainties associated with the
development of product candidates. 

The costs of clinical trials
may vary significantly over the life of a project owing to, but not limited to, the following:

    ●
    per patient trial costs;

    ●
    the number of sites included in the clinical trials;

    ●
    the countries in which the clinical trials are conducted;

    ●
    the length of time required to enroll eligible patients;

    ●
    the number of patients that participate in the clinical trials;

    ●
    the number of doses that patients receive;

    ●
    the cost of comparative agents used in clinical trials;

    ●
    the drop-out or discontinuation rates of patients;

    ●
    potential additional safety monitoring or other studies requested by regulatory agencies;

    ●
    the duration of patient follow-up;

    ●
    the efficacy and safety profile of the product candidate; and

    ●
    the cost of manufacturing, finishing, labelling and storage drug used in the clinical trial.

We do not expect any of our
product candidates to be commercially available for at least the next several years, if ever. We expect to continue to incur significant
expenses and increasing operating losses for the foreseeable future, which may fluctuate significantly from quarter-to-quarter and year-to-year.
We anticipate that our expenses will increase substantially as we:

    ●
    continue research and development, including preclinical and clinical development of our existing product candidates;

    ●
    potentially seek regulatory approval for our product candidates;

    ●
    seek to discover and develop additional product candidates;

    ●
    establish a commercialization infrastructure and scale up our manufacturing and distribution capabilities to commercialize any of our product candidates for which we may obtain regulatory approval;

    ●
    seek to comply with regulatory standards and laws;

    ●
    maintain, leverage and expand our intellectual property portfolio;

    ●
    hire clinical, manufacturing, scientific and other personnel to support our product candidates development and future commercialization efforts;

    ●
    add operational, financial and management information systems and personnel; and

    ●
    incur additional legal, accounting and other expenses in operating as a public company.

23

Results of Operations 

Comparison of the Three Months Ended March
31, 2025 and 2024

The following table summarizes
our results of operations for the periods indicated:

    Three Months Ended March 31,  

    (in thousands) 
    202